Biofrontera AG

  • WKN: 604611
  • ISIN: DE0006046113
  • Land: Deutschland

Nachricht vom 23.10.2019 | 08:00

Biofrontera AG: Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019

DGAP-News: Biofrontera AG / Key word(s): Conference

23.10.2019 / 08:00
The issuer is solely responsible for the content of this announcement.


Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019

Leverkusen, Germany, October 23, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, was presented with the "Poster of the Day" award at the renowned Fall Clinical Dermatology Conference in Las Vegas from October 17 to 20, 2019 for its latest Phase III clinical trial.

During the conference, the company presented four scientific posters on the application of photodynamic therapy (PDT) for the treatment of actinic keratoses (AK) and basal cell carcinomas. The poster presentation of the results of the Phase III clinical trial on the safety and efficacy of conventional PDT with BF-200 ALA (development name for Ameluz(R)) and the BF-RhodoLED(R) lamp for the treatment of mild to severe AKs on the extremities or the trunk/neck (original title: Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial) was selected "Poster of the Day" by the attending dermatologists.

"The great interest of US-dermatologists at the conference confirms the growth of the PDT market in the US. We are proud of the recognition of our positive data from our latest phase III trial with BF-200 ALA received," commented Prof. Dr. Hermann Lübbert, Chief Executive Officer of Biofrontera. "The annual Fall Clinical Dermatology Conference offers us the opportunity to network with leading dermatologists in the US and inform them about our products."

The annual Fall Clinical Dermatology Conference is the second largest conference for dermatologists in the US and took place from October 17 to 20, 2019 in Las Vegas.
-End-

For enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer


+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44 (0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets XepiTM, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



23.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Media and Games Invest wächst dynamisch und profitabel

Innerhalb des Konzerns Media and Games Invest sind der wachstumsstarke Game-Publisher gamigo AG sowie Unternehmen aus dem dynamischen Bereich „Digital Media“ gebündelt. Der Wachstumskurs der Gesellschaft soll sowohl auf Basis eines anhaltenden anorganischen Wachstums sowie durch den Ausbau des bestehenden Geschäftes fortgesetzt werden. Im Rahmen unserer Initial-Coverage-Studie haben wir ein Kursziel von 1,90 € je Aktie ermittelt und vergeben das Rating KAUFEN..

News im Fokus

Vonovia SE: Erfolgreiches Pflichtangebot - Vonovia wird nach Settlement 94 Prozent der Hembla-Aktien halten (News mit Zusatzmaterial)

10. Dezember 2019, 16:06

Aktuelle Research-Studie

amalphi AG

Original-Research: amalphi AG (von Sphene Capital GmbH): Buy

11. Dezember 2019